Advanced Multiple Sclerosis: Progressive MS Epidemiology



Similar documents
Clinical Features and Treatment Outcomes in MS An Update from Contemporary Cohorts

Disease Modifying Therapies (DMTs) in Multiple Sclerosis

Supplementary appendix

Measurement Issues in Short Term Clinical Trials. Brian Healy, PhD

ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate

06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute

Supplementary Online Content

Sensitive and reproducible clinical rating

Using the MS Clinical Course Descriptions in Clinical Practice

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Integrating New Treatments: A Case Based Approach

Treatment Optimization in MS: When to Start, When to Shift, when to Stop

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

Immunex Corporation Novantrone (Mitoxantrone HCL) P&CNS Advisory Committee Briefing Document. Page 020

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

acquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare

Rational basis for early treatment in MS. Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València

Natural history of multiple sclerosis: risk factors and prognostic indicators Sandra Vukusic a,b,c,d and Christian Confavreux a,b,c,d

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre

Natalizumab (Tysabri) and PMLthe current figures. Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str Langen GERMANY

Treatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD

Multiple Sclerosis: An imaging review and update on new treatments.

FastTest. You ve read the book now test yourself

Life with MS: Striving for Maximal Independence & Fulfillment

National MS Society Information Sourcebook

The New England Journal of Medicine

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

doi: /brain/awq118 Brain 2010: 133;

Personalised Medicine in MS

Clinical features. Chapter 2. Clinical manifestations. Course

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON

MRI in Differential Diagnosis

Version History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b

Optimizing Therapy in Progressive MS: Treatment Options

MRI in drug development: Lessons from MS

How To Use A Drug In Multiple Sclerosis

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011

Accuracy in Space and Time: Diagnosing Multiple Sclerosis Genzyme Corporation, a Sanofi company.

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria

MS ECHO: Update on MS treatment. Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology

NHS BOURNEMOUTH AND POOLE AND NHS DORSET

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients

Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December Reference : NHSCB/D4/c/1

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004.

A New MS Consortium for A New MS Clinical Outcome Measure

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

AUBMC Multiple Sclerosis Center

Progress in MS: Current and Emerging Therapies

AUBAGIO (teriflunomide) oral tablet

Grand Rounds: Exploring Current Therapeutic Agents in Multiple Sclerosis Management. CME University, FreeCME.com, Powerpak.com

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center

Progress in the field: therapeutic improvements for all patients?

2.1 Who first described NMO?

Summary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary

LONG-TERM BENEFITS OF EARLY TREATMENT IN MULTIPLE SCLEROSIS: AN INVESTIGATION UTILIZING A NOVEL DATA COLLECTION TECHNIQUE DEVON S. CONWAY, M.D.

SECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage

How To Know If You Have A Cure For Multiple Sclerosis

OHTAC Recommendation

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors

Chapter 10. Summary & Future perspectives

Held, Heigenhauser, Shang, Kappos, Polman: Predicting the On-Study Relapse Rate for Multiple Sclerosis Patients in Clinical Trials

Study Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch

CNS DEMYLINATING DISORDERS

Voting for your top research questions Survey

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

What is Multiple Sclerosis? Gener al information

Approved Beta Interferons in Relapsing-Remitting Multiple sclerosis: Is There an Odd One Out?

What is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter

How to evaluate medications in Multiple Sclerosis when placebo controlled RCTs are not feasible

Summary chapter 2 chapter 2

How To Treat Ms With Ifnb-1B

SammyJo s MS-LDN Timeline

ORIGINAL CONTRIBUTION

Laquinimod Polman, C. et al. Neurology 2005;64:

MULTIPLE SCLEROSIS Update. Disclosures. Multiple Sclerosis. I do not have any disclosures. E. Torage Shivapour, M.D.

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010

Cost-Effectiveness of Interferon Beta-1a, Interferon Beta-1b, and Glatiramer Acetate in Newly Diagnosed Non-primary Progressive Multiple Sclerosis

Oxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients

Rx Atlas. The Canadian. Third Edition. The following pages are an excerpt from. December 2013

MSTAC Initial Application

A Letter From the MS Coalition

Stroke Rehabilitation Triage Severe Strokes

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

Disease Modifying Therapies for MS

Multiple sclerosis (MS) is a chronic, neurodegenerative

Advances in the Use of MRI in the Management of MS. The Role of MRI in MS Management. Jack H. Simon Portland, Oregon

News on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS

Original Policy Date

Spinal Muscular Atrophy

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

Clinically isolated syndrome (CIS)

STARTING AND SWITCHING MULTIPLE SCLEROSIS THERAPY

PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft

A list of FDA-approved testosterone products can be found by searching for testosterone at

Transcription:

Advanced Multiple Sclerosis: Progressive MS Epidemiology CMSC 2007-Washington, DC Mitchell T. Wallin, MD, MPH Associate Director-Clinical Care VA MS Center of Excellence-East East Associate Professor of Neurology Georgetown University Medical School

Progressive MS: Epidemiologic Features I.. Definitions & Measures of Morbidity II. Risk Factors for Progression III. Treatment Issues in Progressive MS

Multiple Sclerosis Subtypes (Coyle P, 2002 and Lublin F, et al Neurology 1996)

Prevalence of Subtypes of MS Primaryprogressive (PP) 10% Progressiverelapsing (PR) 5% (N = 3019) Secondary-progressive (SP) 30% Relapsing-remitting (RR) 55% Jacobs et al. Mult Scler. 1999;5:369-376.

Progressive MS Definitions The RR-SP MS Transition Onset of progressive disability x 6 mo Fewer attacks and less recovery during attacks > 50% make transition by 10 yrs from MS onset Up to 90% by 25 yrs from MS onset Benign MS and Progression EDSS < 2-33 at 10 years from onset Progression (>( EDSS 3) at 20 years from onset from baseline EDSS < 2 at 10 yrs 30 % in Canadian Population (Sayao, 2007) 7% in Olmsted County Population (Pittock, 2004)

McDonald Diagnostic Criteria Primary Progressive MS Polman C, Ann Neurol, 2005 Insidious course with one year of steady progression of clinical deficits + two of the following: Positive Positive Brain MRI (9 T2 lesions or 4 or more T2 lesions with positive VEP) Positive Positive spinal cord MRI (2 focal T2 lesions) Positive Positive CSF (OCB, or increased IgG index)

Secondary Progressive MS vs. Primary Progressive MS RR-SP MS PP MS Age at onset (mean) 30 yrs 40 yrs Sex ratio (M:F) 2:1 1:1 Race --- --- Onset symptoms Sensory, visual Paraparesis

Multiple Sclerosis Morbidity Scales Kurtzke Expanded Disability Status Score Scale is a central clinical measure in most longitudinal studies ranges from: 0 = normal 4 = walks unaided for greater than 500 meters 5 = walks unaided for greater than 100 meters 6 = needs a cane to walk 100 meters 7 = restricted to wheelchair, walks less than 20 meters with aid 8 = confined to bed/wheelchair, use of arms 10 = death Cognitive problems, fatigue, sexual function, job capabilities, and social factors do not weigh heavily in EDSS Similar Scales: EDMUS-GS (Grimaud, 1999), Disease Steps (Hohol, 1999), PDDS (Schwartz, 1999)

Multiple Sclerosis Morbidity Scales Multiple Sclerosis Functional Composite measure measure of motor function of legs (25 timed walk) motor function of arms (9-Hole Peg) cognition (PASAT) adds adds information to the Kurtzke EDSS first first used in a phase 3 clinical trial of intramuscular interferon-beta 1a (Cohen, et al 2001)

Measures of Morbidity for MS Progression Clinical Relapses Global Neurological Disability: EDSS, MSFC Other morbidity scales Imaging: T2, T1, & Gd enhancing lesions, atrophy DT MRI, MRS, fmri

Brain Atrophy as a Measure of Morbidity Bermel, 2006 Clinical-imaging imaging paradox of MS Brain atrophy begins early in RR MS RR MS 0.6-1.4%/yr SP MS 0.6-0.8%/yr 0.8%/yr PP MS 0.74-1.3%/yr Whole brain gray matter volume & disability EDSS r = -0.46, p=0.004 25 timed walk: r = -0.52, p= 0.002

Atrophy of Caudate Nuclei in MS (Bermel, 2006) Box plot of normalized caudate volumes; MS (N=24) and age-matched healthy control s (N=10) Caudate nucleus of 50 yr old male with MS (green) and normal control (pink)

Cervical Cord Atrophy SP & PP MT ratio cervical cord histograms overlap Cervical cord atrophy separates PP vs. RR MS (Bieniek, 2006): PP MS: 67.8mm 2 RR MS: 72.7mm 2 in Progressive MS Healthy ctls: 73.4mm 2 (p=0.007) Rovaris, 2001

Progressive MS: Epidemiologic Features I.. Definitions & Measures of Morbidity II. Risk Factors for Progression III. Treatment Issues in Progressive MS

Clinical & Demographic Predictors of Progressive Disability in MS Favorable Risk Factors Young age at onset Female Sex Race: White Onset sx: optic neuritis, sensory RR disease onset Unfavorable Risk Factors Older age at onset Male sex Race: African American Onset sxs: motor, cerebellar, sphincter Severe disability after first attack Short interval between first-second attack High frequency of attacks in first 5 yrs Progressive disease from onset

Predictors of Long-term Disability in RR MS (Langer-Gould, 2007) Sphincter symptoms at onset Systematic review of the literature 1966-2005 Strongest predictors Sphincter sxs : HR 1.1-3.1 Incomplete recovery first attack: HR 1.3-3.3 3.3 Short interval between 1 st - 2 nd attack: HR 1.6-1.9 1.9 Incomplete recovery after first attack

Predictors of Long-term Disability in RR MS (Langer-Gould, 2007) Age at onset Age: Older age at onset associated with worse prognosis in 9/10 studies. Sex: Men have worse prognosis vs. women (5 studies) No significant sex difference (5 studies) Male sex

Longitudinal Follow-up of Benign MS at 10 years (Sayao, 2007) 200 MS pts with EDSS < 3 at 10 yrs from onset from British Columbia Database Conversion to SP MS in 23% 10 -year EDSS score was only significant predictor of progression

Initial Course of MS and Time to EDSS 4 and EDSS 6 (Confavreux, 2000) Median time to EDSS 4 RR Onset: 11.4 yrs Progressive Onset: 0 yrs Median time EDSS 4 to 6 RR Onset: 5.7 yrs Progressive Onset: 5.4 yrs EDSS 4 Threshold: once EDSS 4 is reached, progression in MS is not affected by relapses

Influence of Initial Course on Age to Reach EDSS End-Points (Confavreux, 2006 ) RR MS were older than PP MS to reach EDSS 4 (Graph A) & EDSS 6 (Graph B); 95% CI overlap Age to reach EDSS 7 between groups similar (Graph C) SP MS had younger age of assignment of EDSS 4, 6, and 7 vs. PP MS

Relapses and Progression in MS (Kremenchutzky, 2006) Three subgroups defined: PP MS (N=219) SP MS (N=146) Single attack before onset of progression (SAP; N=140) PP had the worse outcome vs. SP and SAP based on time from onset of MS No difference in time to reach DSS 6, 8 and 10 from onset of progression Progressive course independent of relapses

Relapse-induced MS Disability (Lublin, 2007) Placebo Arm of NMSS Clinical Trial Dataset (N=224) Mean EDSS scores plotted before, during and after relapses 42% pts had residual deficit EDSS 0.5 and 28% with lasting EDSS > 1 point Relapse associated stepwise worsening supported

Age and Disability Progression

African Americans and MS Progression (Cree, et al 2004) Large retrospective cohort of AA (N=375) vs. CA (N=427) Median time to EDSS 6 (16 yrs vs. 22 yrs p=0.0001) Median time to EDSS 7 (30 yrs vs. 38 yrs) Adjusted Cox Hazard Ratio: 1.67 for walking with cane (p < 0.001)

VA Longitudinal MS Study (VALOMS) Demographic & Clinical Data Overview Variable African Americans (N=41) White Americans (N=40) p- value Male:Female Ratio 1.6 4.7 0.048* Mean age at first symptom onset 32.6 ± 8.4 37.4 ±10.4 0.024* Mean MS disease duration (yrs) 12.1 ± 6.2 13.1± 6.4 0.53 Median time from onset to diagnosis (yrs) 3.0 ± 3.9 4.8 ± 5.1 0.06 Median time from diagnosis to treatment (mo) 44.7 25 0.12 Median time to SP MS 7.2 ± 3.7 4.9 ± 3.6 0.14 Median time to EDSS 6 6.4 ± 4.6 4.6 ± 3.3 0.20

VA Longitudinal MS Study (VALOMS) MS Onset to EDSS 6: AA vs. CA Log Rank (Mantel-Cox)= 0.41

Progressive MS: Epidemiologic Features I.. Definitions & Measures of Morbidity II. Risk Factors for Progression III. Treatment Issues in Progressive MS

Does treatment impact disability in progressive MS? SP MS: Some short-term data affirmative: Interferonbeta and immunosuppressive therapy No evidence for long-term benefits of any disease modifying therapy PP MS: No therapy that impacts disability

Interferon-beta Clinical Trials (adapted from Goodkin D, Int MS J 2005) Interferon beta Trial Size Clinical Activity MRI Activity Clinical Severity Phase III Trial RR MS IFN beta 1b SC 372 NS Phase III Trial RR MS IFN beta 1a IM 301 Phase III Trial RR MS IFN beta 1a SC 560 EUSPMS (Interferon beta 1b SC) 718 NASPMS (Interferon beta 1b SC) 939 NS IMPACT (Interferon beta 1a IM) 436 NS SPECTRIMS (Interferon beta 1a SC) 506 NS significant p<0.05 significant p<0.01-0.05

Interferon beta Trials in SP MS (Rovaris, 2006)

Immunosuppressive Options for SP MS Pulsed IV corticosteroids (Goodkin, 1998) Mitoxantrone (Hartung, 2002) Methotrexate (Gray, 2006) Cyclophosphamide (LaMantia, 2007; Drachman 2005) Azathioprine (Yudkin, 1991) Mycophenolate mofetil (Frohman, 2004) Autologous Stem Cell Transplant (Saccardia, 2006)

Treatment Options for Progressive MS Current therapies benefit SP with relapses/active MRI Failure of many immune modifying drugs used in RR MS Once the cascade of events leading to axonal loss is established, immunosuppressive treatments are inadequate in slowing disease course New treatment approaches needed Neuroprotection Neuroregeneration Neurorehabilitation

Progressive MS Epidemiology Conclusions EDSS 4 is a disability threshold Age at achieving disability landmarks is not related to the initial MS course Benign MS does progress Current Risk factors for progression inadequate: reliable biomarker for MS morbidity needed Concept of MS as a diffuse CNS disease with a major neurodegenerative component supported by population data